US · Healthcare · Biotechnology
EPS came in at -3.03 against a street estimate of -2.58 — a miss of 17.4%.
Analysts rate BioNTech SE a buy (14 buy, 6 hold, 1 sell out of 21) with an average price target of $116.21.
MIXED BioNTech posted weak Q2 revenue (EUR 106M, down 59% YoY) due to collapsed COVID demand and inventory use. Late-stage pipeline advanced with pumitamig Phase II data across tumors; gotistobart showed strong OS signals. FY26 guidance cut 21% midpoint to EUR 1.6–1.9B. Q2 2026 COVID vaccine demand weakness spans all geographies; Germany most acute due to direct market model and inventory drawdown strategy. Analysts pressed on Elfe-D competitive positioning (safety profile vs peers), revenue miss drivers (COVID 80%, lost milestone 20%), and ROSETTA LUNG-02 timing (event-driven; PFS interim before OS). Management emphasized data-driven approach, partner efficiency, and cautious optimism on late-stage readouts despite guidance reset. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 3.01% |
| PRIMECAP Management Company | 1.50% |
| Dodge & Cox | 1.46% |
| Flossbach von Storch AG | 0.89% |
| T. Rowe Price Investment Management,Inc. | 0.82% |
| BlackRock Inc | 0.74% |
| Temasek Holdings Ltd. | 0.60% |
| BNP Paribas Arbitrage, SA | 0.53% |
| Document | Date |
|---|---|
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • BioNTech’s AHEAD-MERIT Phase 2/3 trial did not meet its first dual primary endpoint: progression-free survival (PFS). • BNT113 pl | 2026-10-13 |
| Current report (6-K) · Q3 2026 OTHER NOTABLE POINTS • BioNTech announced the appointment of KPMG AG Wirtschaftsprüfungsgesellschaft (“KPMG”) as its new independent auditor for the | 2026-09-18 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • In updated stage 1 data from the PRESERVE-003 Phase 3 trial, gotistobart produced median overall survival of 18.5 months versus 10 | 2026-09-14 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • On August 28, 2026, BioNTech announced it will terminate the Phase 2 clinical trial BNT122-01 (NCT04486378). • The trial evaluate | 2026-08-28 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Pfizer and BioNTech received U.S. FDA approval for their 2026–2027 COVID-19 vaccine formula, COMIRNATY XFG. • The vaccine targets | 2026-08-27 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Q2 2026 revenue was €105.6 million, down from €260.8 million in Q2 2025. • H1 2026 revenue was €223.7 million, down from €443.6 | 2026-08-04 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Q2 2026 revenue was €105.6 million, down from €260.8 million in Q2 2025, mainly because of lower COVID-19 vaccine demand. • Q2 IF | 2026-08-04 |
| Quarterly results (6-K) · Q1 2026 HEADLINE NUMBERS • Q1 2026 revenue was €118.1 million, down from €182.8 million in Q1 2025. • COVID-19 vaccine revenue fell to €66.9 million from €1 | 2026-05-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BioNTech SE — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.